GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 111 filers reported holding GENMARK DIAGNOSTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $121,000 | – | 18,600 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEEDHAM INVESTMENT MANAGEMENT LLC | 1,443,400 | $5,947,000 | 1.68% |
| Casdin Capital, LLC | 3,365,000 | $13,864,000 | 1.47% |
| Lyon Street Capital, LLC | 191,656 | $790,000 | 1.26% |
| CADIAN CAPITAL MANAGEMENT, LP | 3,489,055 | $14,375,000 | 0.71% |
| Portolan Capital Management | 893,090 | $3,680,000 | 0.55% |
| Eversept Partners, LP | 524,257 | $2,159,939 | 0.54% |
| Bullseye Asset Management LLC | 78,961 | $325,000 | 0.39% |
| Parkman Healthcare Partners LLC | 200,000 | $824,000 | 0.38% |
| Granite Investment Partners, LLC | 757,878 | $3,122,000 | 0.20% |
| Bellevue Group AG | 2,411,926 | $9,937,000 | 0.19% |